Products IFDA Approved Molecules Dimethyl FumarateMw.: 144.13 g/molAnti-inflammatory, Cytoprotective Effect, Which both likely involved in its action in multiple sclerosis patients Tofacitinib CitrateMw.: 504.5 g/mol Antirheumatic,Disease Modifying,Janus Kinase Inhibitor EmpagliflozinMw.: m450.91 g/mol Antidiabetic agent, Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor ApixabanMw.: 459.50 g/molFactor Xa Inhibitor,Direct Oral Anticoagulant (DOAC) Exatecan MesylateMw.: 435.4 g/molTopoisomerase I Inhibitor,Anti-tumor DalfampridineMw.: 94.12 g/molPotassium Channel Blocker BortezomibMw.: 384.24 g/molAntineoplastic Agent,Proteasome Inhibitor Sorafenib TosylateMw.: 637.03 g/molAntineoplastic Agent,Tyrosine Kinase Inhibitor,Vascular Endothelial growth Factor (VEGF) Inhibitor Zoledronic Acid MonohydrateMw.: 290.1 g/molBisphosphonate Derivative Developed Molecules Sunitinib MalateMw.: 532.6 g/molMulti-specific Tyrosine Kinase Receptor Inhibitor DeruxtecanMw.: 1034.1 g/molAnti-body Drug Conjugate OxaliplatinMw.: 397.29g/molPlatinum-based chemotherapeutic class of drugs LenalidomideMw.: 259.26 g/molAntineoplastic Agent,Angiogenesis Inhibitor Glatiramer AcetateMw.: 623.7 g/molImmunomodulator,Multiple Sclorosis Treatment DeferasiroxMw.: 373.4 g/molIron Chelator TicagrelorMw.: 522.6g/molAntiplatelet Medications LinagliptinMw.: 472.5g/molDipeptidyl Peptidase-4 (DPP-4) Inhibitors Nilotinib Hydrochloride Monohydrate Mw.: 584.0 g/molAntineoplastic Agent,BCR-ABL Tyrosine Kinase Inhibitor Under Development Molecules IbrutinibMw.: 440.5 g/molTyrosine Kinase Inhibitor VoriconazolMw.: 349.3 g/molAntifungal Medication Abiraterone AcetateMw.: 391.5 g/molAnti-androgens (anti-testosterone)